Market World Active Pharmaceutical Ingredients Market | Page 3

Application Insights
Cancer, neurological disorders & CNS, endocrinal disorders and cardiovascular diseases are some of the major
applications of the API. In 2015, CVD (cardiovascular diseases) dominated the market owing to its high rate of
prevalence and high product availability. CVD has been reported as the major cause of death in the U.S since
many years.
In addition, oncology is expected to be the fastest-growing segment and is estimated to witness the CAGR of 7%
owing to high number of products waiting approval. Moreover, increasing prevalence of cancer worldwide is
anticipated to further boost market.
Regional Insights
In 2015, API market was dominated by the North America and is anticipated to retain its position in upcoming
years owing to encouraging government initiatives for generic drug usage, rising R&D expenditure, and
technological advancements in the drug manufacturing practices.
Asia Pacific is anticipated to be the region with fastest growth owing to the increasing availability of cheap and
affordable labour. Hence, key major companies are setting up their API production plants in developing
countries of Asia Pacific such as China and India.
Competitive Insights
One of the key manufacturers of the API (Active pharmaceutical ingredients) is Teva Pharmaceuticals Ltd. Some
of the additional key players in this industry includes Boehringer Ingelheim GmbH, AbbVie, Inc., Merck & Co.,
Inc. and Cipla, Inc., New molecule launches, collaborations, acquisitions, and regional expansions are some
strategic initiatives taken by these Key players to retain their position.
Market Segment:
API Type of Synthesis Outlook (Revenue, USD Billion, 2014 - 2025)
• Biotech
• Monoclonal antibodies
• Recombinant proteins
• Vaccines
• Synthetic